Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in Cd39/Entpd1 null Mice

Xiaofeng Sun, Lihui Han, Pankaj Seth, Shu Bian, Linglin Li, Eva Csizmadia, Wolfgang G. Junger, Moritz Schmelzle, Anny Usheva, Elliot B. Tapper, Gyorgy Baffy, Vikas P. Sukhatme, Yan Wu, Simon C. Robson – 1 August 2012 – Liver cancer is associated with chronic inflammation, which is linked to immune dysregulation, disordered metabolism, and aberrant cell proliferation. Nucleoside triphosphate diphosphohydrolase‐1; (CD39/ENTPD1) is an ectonucleotidase that regulates extracellular nucleotide/nucleoside concentrations by scavenging nucleotides to ultimately generate adenosine.

Use of N‐acetylcysteine during liver procurement: A prospective randomized controlled study

Francesco D'Amico, Alessandro Vitale, Donatella Piovan, Alessandra Bertacco, Rafael Ramirez Morales, Anna Chiara Frigo, Domenico Bassi, Pasquale Bonsignore, Enrico Gringeri, Michele Valmasoni, Greta Garbo, Enrico Lodo, Francesco Enrico D'Amico, Michele Scopelliti, Amedeo Carraro, Martina Gambato, Alberto Brolese, Giacomo Zanus, Daniele Neri, Umberto Cillo – 1 August 2012 – Antioxidant agents have the potential to reduce ischemia/reperfusion damage to organs for liver transplantation (LT).

α5β1‐integrins are sensors for tauroursodeoxycholic acid in hepatocytes

Holger Gohlke, Birte Schmitz, Annika Sommerfeld, Roland Reinehr, Dieter Häussinger – 1 August 2012 – Ursodeoxycholic acid, which in vivo is converted to its taurine conjugate tauroursodeoxycholic acid (TUDC), is a mainstay for the treatment of cholestatic liver disease. Earlier work showed that TUDC exerts its choleretic properties in the perfused rat liver in an α5β1 integrin‐mediated way. However, the molecular basis of TUDC‐sensing in the liver is unknown.

Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans

Jennifer E. Lambert, Vincent G. Bain, Edmond A. Ryan, Alan B.R. Thomson, Michael T. Clandinin – 1 August 2012 – Hepatitis C virus (HCV) exerts a profound influence on host lipid metabolism. It has been suggested that the synthesis of both fatty acids (FA) and cholesterol is dysregulated in HCV but this has not been directly quantified in humans. The purpose of this study was to measure lipogenesis and cholesterol synthesis using stable isotopes in patients with HCV (n = 5) and healthy control (n = 9) subjects recruited from the University of Alberta hospital.

Rho‐kinase–dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis

Ying‐Ying Yang, Yi‐Tsau Huang, Tzung‐Yan Lee, Che‐Chang Chan, Yi‐Chen Yeh, Kuei‐Chuan Lee, Han‐Chieh Lin – 30 July 2012 – During liver transplantation, nonalcoholic steatohepatitis (NASH) aggravates ischemia/reperfusion (IR) injury by activating various kinases and subsequently releasing cytokines and chemokines. Nonetheless, the effect of the multikinase inhibitor sorafenib on IR liver injury in rats with NASH has never been explored. Our study was designed to determine this effect and associated mechanisms in NASH rats.

Recipient outcomes of salvage liver transplantation versus primary liver transplantation: A systematic review and meta‐analysis

Zhenhua Hu, Wei Wang, Zhiwei Li, Sunyi Ye, Shu‐Sen Zheng – 30 July 2012 – Salvage liver transplantation (SLT), or liver transplantation after liver resection (LR), has been performed after primary LR for many years. However, the true outcomes and risks of SLT versus primary liver transplantation (PLT) remain unclear. We performed a systematic review and meta‐analysis to evaluate the survival rate of SLT recipients and the incidence of postoperative complications. Among 2799 screened references, 7 eligible studies were identified.

Renal dysfunction in liver transplant recipients: Evaluation of the critical issues

Marc L. Weber, Hassan N. Ibrahim, John R. Lake – 30 July 2012 – Major progress has been made in the field of liver transplantation since the first procedure was performed nearly 50 years ago. Despite these improvements, renal dysfunction before and after liver transplantation remains a major complicating factor associated with increased health care costs, morbidity, and mortality. Creatinine‐based estimates of renal function are inaccurate in the setting of end‐stage liver disease and often lead to underdiagnosis and late intervention.

Subscribe to